Table 4.
Prevalence of MetS component by gender according to the Interim consensus (IDF-C) or the modified NCEP ATP III (ATP III-M) criteria
| |
|
Met 0 criteria |
Met 1 criteria |
Met 2 criteria |
Met 3 criteria |
Met 4 criteria |
Met 5 criteria |
|
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gender |
Age |
[n(%)] |
[n(%)] |
[n(%)] |
[n(%)] |
[n(%)] |
[n(%)] |
Total |
||||||
| IDF-Ca | ATPIII-Mb | IDF-Ca | ATPIII-Mb | IDF-Ca | ATPIII-Mb | IDF-Ca | ATPIII-Mb | IDF-Ca | ATPIII-Mb | IDF-Ca | ATPIII-Mb | |||
| |
32-44 |
693(46.5) |
791(53.1) |
456(30.6) |
467(31.4) |
219(14.7) |
171(11.5) |
86(5.8) |
49(3.3) |
31(2.1) |
11(0.7) |
4(0.3) |
0(0.0) |
1489 |
| |
45-54 |
1145(24.5) |
1344(28.8) |
1368(29.3) |
1558(33.3) |
1076(23.0) |
1062(22.7) |
667(14.2) |
539(11.5) |
321(6.9) |
155(3.3) |
98(2.1) |
17(0.4) |
4675 |
| Female |
55-64 |
555(14.2) |
657(16.8) |
915(23.5) |
1082(27.7) |
1019(26.0) |
1150(29.5) |
814(20.9) |
722(18.5) |
448(11.5) |
257(6.6) |
153(3.9) |
36(0.9) |
3904 |
| |
65-74 |
109(6.0) |
121(6.6) |
298(16.4) |
387(21.2) |
507(27.8) |
605(33.2) |
493(27.1) |
511(28.1) |
300(16.5) |
174(9.6) |
114(6.2) |
23(1.3) |
1821 |
| |
≥75 |
66(3.9) |
87(5.2) |
271(16.2) |
341(20.4) |
472(28.2) |
594(35.4) |
490(29.2) |
466(27.8) |
277(16.5) |
166(9.9) |
100(6.0) |
22(1.3) |
1676 |
| |
Total |
2568(18.9) |
3000(22.1) |
3308(24.4) |
3835(28.3) |
3293(24.3) |
3582(26.4) |
2550(18.8) |
2287(16.9) |
1377(10.1) |
763(5.6) |
469(3.5) |
98(0.7) |
13565 |
| |
32-44 |
253(29.4) |
344(40.0) |
256(29.7) |
226(26.2) |
187(21.7) |
179(20.8) |
111(12.9) |
87(10.1) |
43(5.0) |
20(2.3) |
11(1.3) |
5(0.6) |
861 |
| |
45-54 |
409(16.9) |
536(22.2) |
545(22.5) |
709(29.3) |
636(26.3) |
603(24.9) |
518(21.4) |
394(16.3) |
253(10.5) |
153(6.3) |
58(2.4) |
24(1.0) |
2419 |
| Male |
55-64 |
328(11.2) |
475(16.2) |
678(23.1) |
880(30.0) |
827(28.2) |
794(27.1) |
684(23.4) |
546(18.7) |
337(11.5) |
204(7.0) |
76(2.6) |
31(1.1) |
2930 |
| |
65-74 |
123(8.4) |
173(11.8) |
304(20.6) |
450(30.5) |
455(30.9) |
435(29.5) |
378(25.6) |
298(20.2) |
176(11.9) |
97(6.6) |
38(2.6) |
21(1.4) |
1474 |
| |
≥75 |
92(7.6) |
124(10.3) |
295(24.4) |
402(33.3) |
378(31.3) |
360(29.8) |
277(23.0) |
212(17.5) |
132(10.9) |
91(7.5) |
34(2.8) |
19(1.6) |
1208 |
| |
Total |
1205(13.6) |
1652(18.6) |
2078(23.3) |
2667(30.0) |
2483(27.9) |
2371(26.7) |
1968(22.1) |
1537(17.3) |
941(10.6) |
565(6.3) |
217(2.5) |
100(1.1) |
8892 |
|
Overall |
32-44 |
946(40.3) |
1135(48.3) |
712(30.3) |
693(29.5) |
406(17.3) |
350(14.9) |
197(8.4) |
136(5.8) |
74(3.1) |
31(1.3) |
15(0.6) |
5(0.2) |
2350 |
| |
45-54 |
1554(21.9) |
1880(26.5) |
1913(27.0) |
2267(32.0) |
1712(24.1) |
1665(23.5) |
1185(16.7) |
933(13.2) |
574(8.1) |
308(4.3) |
156(2.2) |
41(0.5) |
7094 |
| |
55-64 |
883(12.9) |
1132(16.6) |
1593(23.3) |
1962(28.7) |
1846(27.0) |
1944(28.4) |
1498(21.9) |
1268(18.6) |
785(11.5) |
461(6.7) |
229(3.4) |
67(1.0) |
6834 |
| |
65-74 |
232(7.0) |
294(8.9) |
602(18.3) |
837(25.4) |
962(29.2) |
1040(31.6) |
871(26.4) |
809(24.6) |
476(14.5) |
271(8.2) |
152(4.6) |
44(1.3) |
3295 |
| |
≥75 |
158(5.5) |
211(7.3) |
566(19.6) |
743(25.8) |
850(29.5) |
954(33.1) |
767(26.6) |
678(23.5) |
409(14.2) |
257(8.9) |
134(4.6) |
41(1.4) |
2884 |
| Total | 3773(16.8) | 4652(20.7) | 5386(24.0) | 6502(29.0) | 5776(25.7) | 5953(26.5) | 4518(20.1) | 3824(17.0) | 2318(10.3) | 1328(5.9) | 686(3.1) | 198(0.9) | 22457 | |
aIDF-C (joint interim consensus criteria by IDF and other organization): Diabetes or fasting glucose ≥ 100 mg/dL; Hypertension or SBP ≥ 130 mmHg or DBP ≥ 85 mmHg; Dyslipidemia or HDL < 40 mg/dL for men and HDL < 50 mg/dL for women; Dyslipidemia or Triglycerides ≥ 150 mg/dL; Waist circumference ≥ 85 cm for men and ≥ 80 cm for women.
bATP III-M (modified NCEP ATP III criteria): Diabetes or fasting glucose ≥ 110 mg/dL; Hypertension or SBP ≥ 130 mmHg or DBP ≥ 85 mmHg; Dyslipidemia or HDL < 40 mg/dL for both men and women; Dyslipidemia or Triglycerides ≥ 150 mg/dL; Waist circumference ≥ 90 cm for men and ≥ 80 cm for women.